clinical-pharmacy-2017-scientifictracks-abstracts

7 / 23

alliedacademies
Journal of Pharmacology and Therapeutic Research
Volume 1 Issue 1 Clinical Pharmacy 2017
Notes:
Page 19
December 07-09, 2017 | Rome, Italy
7th World Congress on
Clinical Pharmacy and Pharmacy Practice
Effect of low-dose oral acetylcysteine on
Cisplatin-induced mitochondrial oxidative
stress in patients with head and neck cancer
Patricia Moriel, Marília Berlofa Visacri, Júlia Coelho França
Quintanilha, Larissa Brito Bastos, Camila de Oliveira Vaz, João
Paulo de Oliveira Guarnieri, Carina Malaguti, Anibal Eugenio Vercesi
and Carmen Silvia Passos Lima
University of Campinas, Brazil
C isplatin anticancer drug induces mitochondrial
oxidative stress and acetylcysteine (NAC) is an
antioxidant that has been studied to attenuate cisplatin
oxidative stress and toxicities in animal models. Objective:
To evaluate the effect of low-dose oral NAC on cisplatin-
induced mitochondrial oxidative stress in patients with
head and neck cancer. Methods: This is a randomized
double-blind placebo-controlled trial conducted with 49
patients undergoing treatment with high-dose cisplatin
chemotherapy, concomitant to radiotherapy. Patients were
randomly assigned and were given: (a) NAC syrup, 600 mg
orally once a day at night for 7 consecutive days (two days
before the chemotherapy, on the day of chemotherapy,
and 4 days after chemotherapy), n = 26; or (b) Placebo,
administered similarly to NAC, n = 23. Before and after five
days of the chemotherapy, blood samples were collected
and peripheral blood mononuclear cells were isolated
to perform the MitoSox Red test, a mitochondrial O2•-
marker. Results: The placebo group showed a baseline
mean of 238.4 ± 206.0 M.F.I versus 297.1 ± 268.6 M.F.I in
the NAC group. After first cycle of chemotherapy, placebo
group showed an increase in mitochondrial O2•- (286.8
± 263.9 M.F.I, increase of 48.4 M.F.I) and NAC group a
decrease (287.4 ± 268.6 M.F.I, decrease of 9.7 M.F.I);
however, there was no statistic difference between the
groups (p=0.7952, Mann-Whitney test). In the second
and third cycles of chemotherapy, the results were also
not statically significant. Conclusion: Low-dose oral NAC
did not impact on cisplatin-induced mitochondrial oxidative
stress in patients with head and neck cancer.
Biography
Patricia Moriel is a full Professor in the Faculty of Pharmaceutical Science at
State University of Campinas (UNICAMP), Brazil. She is leader of the Clinical
Pharmacy Group that is involved in the study of pharmacotherapy, drug adverse
events, pharmacovigilance, pharmacokinetic e pharmacogenomics influences
in adverse events, especially in cancer. She has authored more than 45
research articles, awards, conferences and the granting of a research projects.
She has been director of several works of Master in medical and pharmaceutical
science and doctoral theses
Patricia Moriel et al., J Pharmacol Ther Res 2017